Compare Gitlab Inc (GTLB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gitlab Inc trades at $41.09 (market cap $7.11B), while Recursion Pharmaceuticals Inc trades at $3.28 (market cap $1.81B). The key difference: Gitlab Inc is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GTLB | RXRX | |
|---|---|---|
Market Cap | $7.11B | $1.81B |
Sector | Technology | Health |
52-Week High | $51.04 | $6.79 |
52-Week Low | $19.42 | $2.84 |
Enterprise Value | $5.85B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $40.73, up 4.52% today, with a bullish technical signal from moving averages and a consensus analyst price target of $32.92. Recent earnings beats in Q3 2025 to Q1 2026 highlight strong execution, while revenue grew to $759.25 million in 2025. The stock's high P/E of 521.22 reflects growth expectations, but negative net income and cash flow pose challenges.
Outlook: Growth in DevSecOps and AI-driven software demand supports upside, but profitability risks and high valuation require caution. Key catalysts include continued revenue expansion and path to positive cash flow, while competition and execution missteps are primary risks for investors.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
